Shots:

• The complete dose-finding part of P-Ib/II study assessed the safety- feasibility- and RP2D of NBTXR3 (intratumoral inj.) in 20 patients with LA (T3 to T4) or unresectable rectal cancer
• The study showed ORR after CCRT in >70% patients- 90% patients underwent total mesorectal excision (surgery); 17.6% achieved pCR; 50% receiving surgery had good tumor regression; therapy was feasible and was well tolerated at all dose levels
• Nbtxr3 is a novel- potentially first-in-class therapy designed to destroy tumors through physical cell death when activated by radiotherapy.

 ­ Ref: Businesswire | Image: Wikipedia